CHLAMYDIA SCREENING
117. The Strategy specified chlamydia screening
as an area needing development. As already noted, chlamydia is
now the commonest sexually transmitted infection. The fact that
in the majority of cases chlamydia is asymptomatic means that
its prevalence is only likely to be reduced through screening.
118. The Chief Medical Officer's Expert Advisory
Group on Chlamydia argued that specific target populations should
be screened in a variety of healthcare settings. Screening should
be offered to all GUM clinic attenders, in the view of the Group,
as well as to all women seeking termination of pregnancy and their
partners, and to asymptomatic sexually active women aged under
25 (especially teenagers and especially those who have had two
or more partners in a year or a recent partner change). The preferred
settings for testing, in the view of the Group, were General Practice
and Family Planning Clinics. Referral for treatment should then
be made to GUM clinics (although the Group acknowledged that some
individuals would be unwilling to attend). Training would be required
for GPs "who will have to decide whether or not to raise
the issue of testing for a sexually transmitted infection when
the patient is presenting for an unrelated condition".[105]
Professor Anne Johnson of the Department of Population Sciences
at the Royal Free Hospital listed antenatal clinics, abortion
clinics, primary care and possibly the contraception service as
potential settings for clinics, and in particular drew attention
to the difficulty in capturing chlamydia in the male population,
given the limitations of partner tracing and the fact that men
would not access most of the obvious settings. In the absence
of a widespread screening programme she anticipated that chlamydia
would continue to present a "major public health burden".[106]
119. A pilot study to assess the impact of opportunistic
screening for chlamydial infection has been completed at two sites,
Portsmouth and the Wirral. This was funded by the Department and
co-ordinated by the PHLS. The study also looked at the feasibility
of opportunistic screening in a range of primary and secondary
healthcare settings.[107]
In a written answer to Sandra Gidley MP, the Public Health Minister,
Hazel Blears MP said:
The pilots showed that this form of screening
was acceptable to the target group and the professionals with
75% uptake among those offered screening and 95% of those diagnosed
returning for treatment. The national strategy for sexual health
and HIV commits to beginning a programme of opportunistic screening
for chlamydia for targeted groups in 2002. The first 10 screening
sites are currently being selected, and will be approved shortly.
The pace of the roll-out of the programme across the country will
depend on the availability of resources, trained staff and equipment,
and cannot be precisely predicted at this stage.[108]
120. Approximately 17,000 women were tested, equivalent
to about 45% of the sexually active female population aged under
25 years in the area concerned. The results suggested that between
10% and 11% of women aged under 25 and attending healthcare services
may be infected with chlamydia, with the highest rates being recorded
in youth clinics where 17% were found to be positive.[109]
121. Dr Jean Tobin, a consultant in GUM and one of
the managers of the chlamydia screening pilot, told us that the
results of the pilot were so striking she would have preferred
the Department to proceed straight away to a national roll-out
of the screening programme:
It is going to take a while to roll out the programme,
anyway, but I would much rather that than just another ten sites
and expanding very slowly afterwards, because an awful lot of
people are going to be able to get an asymptomatic infection during
that time.[110]
122. Dr Kinghorn told us that the GUM specialty found
it "very difficult to understand why we are rolling out in
dribs and drabs."[111]
Professor Anne Johnson argued that "a population based strategy"
was needed since chlamydia was so widespread in society. However,
Dr Muir Gray, Programme Director for the National Electronic Screening
Programme which is involved in advising on the programme, suggested
that targeted testing of the high risk population was what was
needed. He did not support a call for an immediate national roll
out until national standards for testing, quality assurance of
testing, information giving and communication had been established.[112]
He thought it was important that the results of a follow-up reinfection
study were known before proceeding to a national roll out. A different
view was taken by Dr Gwenda Hughes, for the Communicable Disease
Surveillance Centre of the PHLS, who told us she did not believe
that the benefits arising from refining the screening programme,
in the light of the reinfection study, constituted sufficient
reason for any delay in the screening programme, given the quantity
of untreated infection in the community.[113]
123. We do not think that it is necessary to wait
for the results of the reinfection study before introducing nationally
the chlamydia screening programme. Any additional information
that the reinfection study provides is, in our view, likely only
to lead to modifications in the programme rather than fundamental
reforms. Accordingly we recommend that the NHS must, as a matter
of urgency, move to provide such screening in all family planning
clinics, infertility clinics, termination of pregnancy clinics
and GUM clinics and for women having their first cervical smears.
We also believe that GPs should routinely offer testing to those
aged under 25 years without attempting to second-guess patients'
sexual behaviour.
124. Dr Gray told us that he thought that the best
way of tracing and treating chlamydia in males was via contact
tracing through female contacts. We are not convinced that this
will be sufficient. We gather that the preliminary findings of
the reinfection study suggest a high degree of reinfection in
the community. Men are less likely than women to access any of
the settings where it is suggested that screening can take place.
Given the fact that chlamydia is usually asymptomatic in men,
this poses real problems.
125. We recommend that the Department explores
the possibility of offering screening and advice on STIs, including
chlamydia, to men outside traditional health service settings.
Imaginative solutions will be needed if the male population is
to be engaged. School based services such as that offered by the
Tic Tac project offer one possible avenue for advice, testing
and referral (see below, paragraph 312). We would also like screening
to be offered via community outreach schemes, for example targeting
night clubs or sports clubs, especially in areas where high prevalence
rates are recorded. We also recommend that the Government should
assess the possibility of a much wider screening campaign, including
a national screening day or series of regional screening days,
promoted through a campaign of hard-hitting messages. Such a campaign
should be introduced in an attempt to have a real impact on chlamydia
in the wider population.
The test for chlamydia
126. Testing for chlamydial infection is by means
of urethral samples in men and women, or cervical samples, urine
samples or self-administered vulval swabs in women. Several of
the memoranda draw attention to the greater accuracy and sensitivity
of the newer molecular amplification test, such as the polymerase
chain reaction (PCR) test, and to the fact that, for cost reasons,
this is not always available.[114]
In oral evidence, Dr Tobin suggested that only 10% of clinics
used the PCR test, and that the enzyme immuno-assay (EIA) tests
in common use would have missed 30% of women and 46% of men.[115]
Dr Kinghorn estimated that fewer than 5% of GPs had the PCR test
available to them.[116]
127. We were astonished to learn from Dr Kinghorn
that even the chlamydia screening pilot sites, which had provided
a stark picture of the extent of chlamydia in the population using
the more accurate PCR test, had had to revert to the sub-optimal
test following the completion of the pilots:
In Portsmouth, following the completion of their
studyand they had very strong evidence for using the molecular
testthey had to go back to using the suboptimal test on
the patients they are looking after. That to me is wicked. It
is a situation which prevails across the country. There should
be no argument. The evidence from everywhere says very clearly
that this molecular test is so much better.[117]
128. Professor Johnson pointed out that there were
potential long-term cost savings in the use of the more sensitive
test if PID and infertility were reduced as a consequence of its
introduction, given the very high costs of infertility treatment.[118]
The Public Health Minister acknowledged that urine tests were
"very acceptable" to patients, though she also felt
that the self-swab test, whilst invasive, also had high levels
of acceptability.[119]
129. We believe it is scandalous that a sub-optimal
test, with an accuracy rate markedly below the best tests, is
still widely in use in England for the detection of chlamydia.
Indeed, we believe that health providers would be highly vulnerable
to damages claims made by patients who had received a false negative
diagnosis and had thus not had treatment for chlamydia infection.
We believe that the Department of Health should issue firm guidance
to the effect that the sub-optimal EIA test should be withdrawn
in favour of the molecular amplification test as soon as possible.
In some cases we realise that laboratory services would not be
able to cope with sudden transition to these types of tests. Nevertheless,
the examples of the Netherlands and Sweden, which we visited and
which had long since abandoned EIA testing, convince us that it
must be possible to move to the optimal test and we believe this
should be an urgent priority.
57 Ev 387 (Specialty Societies for Genito-urinary Medicine) Back
58
Ev 387 Back
59
Ev 388 (Specialty Societies for Genito-urinary Medicine) Back
60
Q 518 Back
61
Ev 401 Back
62
Q 519 Back
63
Ev 352 (Dr Ranjani Rani and Dr V Smith) Back
64
Ev 377 (Dr Graz Luzzi) Back
65
Ev 330 (Dr Helen Lacey) Back
66
Ev 363 (Richard Pattman) Back
67
Ev 321 Back
68
Consultant Physicians Working for Patients: The duties, responsibilities
and practice of physicians, 2nd ed, Royal College of Physicians,
November 2001, p 27 Back
69
Q 541 Back
70
Q 520 Back
71
Ev 161; Q557 Back
72
Ev 392 Back
73
Q 514 Back
74
Ev 322 Back
75
Ev 349 (Dr K C Mohanty). Back
76
Ev 330 (Helen Lacey) Back
77
Ev 364 Back
78
Ev 355 Back
79
Ev 326 (Dr Linda Green) Back
80
Ev 324 Back
81
Ev 392 Back
82
Q 1046 Back
83
Q 524 Back
84
Ev 61 Back
85
Q 304 Back
86
Q 304 Back
87
Q 524 Back
88
Q 526 Back
89
Ev 322 (Dr P A Fraser) Back
90
Q 524 Back
91
Q 525. Back
92
Q 525; Report on the Working Group to Examine Workloads on
Genito-urinary Medicine Clinics, (November, 1988) Back
93
Ev 364 Back
94
Ev 365 Back
95
Q 538 Back
96
Q 24 Back
97
Q 1060 Back
98
Ev 349 Back
99
Ev 390 (The Specialty Society for Genito-urinary Medicine) Back
100
Q 591 Back
101
Q 590 Back
102
Q 892 Back
103
Q 1057 Back
104
Q 1058 Back
105
EAG Report Back
106
Q 277 Back
107
See J Catchpole et al, "Evidence based health policy report:
screening for genital chlamydial infection", BMJ,
2000, 321:629-31 Back
108
HC Deb, 19 June 2002, col. 437W Back
109
Q281; Ev 58 Back
110
Q 283 Back
111
Q 587 Back
112
Q 739 Back
113
Q 288 Back
114
See eg Ev 349 (Dr T R Moss); Ev 354 (Nottingham City Hospital) Back
115
Q 280. The PCR test amplifies a fragment of DNA, and will detect
even a single chlamydial cell in a sample. Back
116
Q 574 Back
117
Q 572 Back
118
Q 279 Back
119
Q 1079 Back